Pete Stavropoulos
Stock Analyst at Cantor Fitzgerald
(4.19)
# 589
Out of 4,412 analysts
24
Total ratings
45.83%
Success rate
20.4%
Average return
Main Sectors:
Top Industries:
9 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANNX Annexon | Reiterates: Overweight | n/a | $4.70 | - | 7 | Apr 24, 2024 | |
| VERA Vera Therapeutics | Initiates: Overweight | n/a | $39.65 | - | 1 | Jan 8, 2024 | |
| JSPR Jasper Therapeutics | Reiterates: Overweight | $60 | $20.40 | +194.12% | 3 | Oct 12, 2023 | |
| ALEC Alector | Initiates: Overweight | $13 | $5.25 | +147.62% | 1 | Sep 22, 2023 | |
| RZLT Rezolute | Reiterates: Overweight | $5 | $2.66 | +87.97% | 3 | Sep 19, 2023 | |
| PLRX Pliant Therapeutics | Reiterates: Overweight | $63 | $11.81 | +433.45% | 3 | Aug 22, 2023 | |
| ARCT Arcturus Therapeutics Holdings | Reiterates: Overweight | $54 | $26.55 | +103.39% | 3 | Aug 22, 2023 | |
| ABOS Acumen Pharmaceuticals | Reiterates: Overweight | $13 | $3.17 | +310.09% | 2 | Jul 17, 2023 | |
| IMNM Immunome | Reiterates: Overweight | $8 | $13.73 | -41.73% | 1 | Mar 20, 2023 |
Annexon
Apr 24, 2024
Reiterates: Overweight
Price Target: n/a
Current: $4.70
Upside: -
Vera Therapeutics
Jan 8, 2024
Initiates: Overweight
Price Target: n/a
Current: $39.65
Upside: -
Jasper Therapeutics
Oct 12, 2023
Reiterates: Overweight
Price Target: $60
Current: $20.40
Upside: +194.12%
Alector
Sep 22, 2023
Initiates: Overweight
Price Target: $13
Current: $5.25
Upside: +147.62%
Rezolute
Sep 19, 2023
Reiterates: Overweight
Price Target: $5
Current: $2.66
Upside: +87.97%
Pliant Therapeutics
Aug 22, 2023
Reiterates: Overweight
Price Target: $63
Current: $11.81
Upside: +433.45%
Arcturus Therapeutics Holdings
Aug 22, 2023
Reiterates: Overweight
Price Target: $54
Current: $26.55
Upside: +103.39%
Acumen Pharmaceuticals
Jul 17, 2023
Reiterates: Overweight
Price Target: $13
Current: $3.17
Upside: +310.09%
Immunome
Mar 20, 2023
Reiterates: Overweight
Price Target: $8
Current: $13.73
Upside: -41.73%